BackgroundHuman	O
stem	O
cells	O
are	O
viewed	O
as	O
a	O
possible	O
source	O
of	O
neurons	O
for	O
a	O
cell	O
-	O
based	O
therapy	O
of	O
neurodegenerative	O
disorders	O
,	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

Several	O
protocols	O
that	O
generate	O
different	O
types	O
of	O
neurons	O
from	O
human	O
stem	O
cells	O
(	O
hSCs	O
)	O
have	O
been	O
developed	O
.	O

Nevertheless	O
,	O
the	O
cellular	O
mechanisms	O
that	O
underlie	O
the	O
development	O
of	O
neurons	O
in	O
vitro	O
as	O
they	O
are	O
subjected	O
to	O
the	O
specific	O
differentiation	O
protocols	O
are	O
often	O
poorly	O
understood	O
.	O

ResultsWe	O
have	O
designed	O
a	O
focused	O
DNA	O
(	O
oligonucleotide	O
-	O
based	O
)	O
large	O
-	O
scale	O
microarray	O
platform	O
(	O
named	O
""""	O
NeuroStem	O
Chip	O
""""	O
)	O
and	O
used	O
it	O
to	O
study	O
gene	O
expression	O
patterns	O
in	O
hSCs	O
as	O
they	O
differentiate	O
into	O
neurons	O
.	O

We	O
have	O
selected	O
genes	O
that	O
are	O
relevant	O
to	O
cells	O
(	O
i	O
)	O
being	O
stem	O
cells	O
,	O
(	O
ii	O
)	O
becoming	O
neurons	O
,	O
and	O
(	O
iii	O
)	O
being	O
neurons	O
.	O

The	O
NeuroStem	O
Chip	O
has	O
over	O
1,300	O
pre	O
-	O
selected	O
gene	O
targets	O
and	O
multiple	O
controls	O
spotted	O
in	O
quadruplicates	O
(	O
~46,000	O
spots	O
total	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
NeuroStem	O
Chip	O
in	O
detail	O
and	O
describe	O
the	O
special	O
advantages	O
it	O
offers	O
to	O
the	O
fields	O
of	O
experimental	O
neurology	O
and	O
stem	O
cell	O
biology	O
.	O

To	O
illustrate	O
the	O
utility	O
of	O
NeuroStem	O
Chip	O
platform	O
,	O
we	O
have	O
characterized	O
an	O
undifferentiated	O
population	O
of	O
pluripotent	O
human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
,	O
cell	O
line	O
SA02	B
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
performed	O
a	O
comparative	O
gene	O
expression	O
analysis	O
of	O
those	O
cells	O
versus	O
a	O
heterogeneous	O
population	O
of	O
hESC	O
-	O
derived	O
cells	O
committed	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
PA6	B
stromal	O
cells	O
for	O
16	O
days	O
and	O
containing	O
a	O
few	O
tyrosine	O
hydroxylase	O
-	O
positive	O
dopaminergic	O
neurons	O
.	O

ConclusionWe	O
characterized	O
the	O
gene	O
expression	O
profiles	O
of	O
undifferentiated	O
and	O
dopaminergic	O
lineage	O
-	O
committed	O
hESC	O
-	O
derived	O
cells	O
using	O
a	O
highly	O
focused	O
custom	O
microarray	O
platform	O
(	O
NeuroStem	O
Chip	O
)	O
that	O
can	O
become	O
an	O
important	O
research	O
tool	O
in	O
human	O
stem	O
cell	O
biology	O
.	O

We	O
propose	O
that	O
the	O
areas	O
of	O
application	O
for	O
NeuroStem	O
microarray	O
platform	O
could	O
be	O
the	O
following	O
:	O
(	O
i	O
)	O
characterization	O
of	O
the	O
expression	O
of	O
established	O
,	O
pre	O
-	O
selected	O
gene	O
targets	O
in	O
hSC	O
lines	O
,	O
including	O
newly	O
derived	O
ones	O
,	O
(	O
ii	O
)	O
longitudinal	O
quality	O
control	O
for	O
maintained	O
hSC	O
populations	O
,	O
(	O
iii	O
)	O
following	O
gene	O
expression	O
changes	O
during	O
differentiation	O
under	O
defined	O
cell	O
culture	O
conditions	O
,	O
and	O
(	O
iv	O
)	O
confirming	O
the	O
success	O
of	O
differentiation	O
into	O
specific	O
neuronal	O
subtypes	O
.	O

Modern	O
DNA	O
microarrays	O
permit	O
a	O
comprehensive	O
analysis	O
of	O
quantitative	O
and	O
qualitative	O
changes	O
in	O
RNA	O
transcript	O
abundance	O
,	O
outlining	O
the	O
cross	O
-	O
sections	O
of	O
gene	O
expression	O
and	O
alterations	O
of	O
these	O
in	O
response	O
to	O
genetic	O
or	O
environmental	O
stimuli	O
.	O

Genome	O
-	O
scale	O
microarrays	O
(	O
cDNA-	O
or	O
oligonucleotide	O
-	O
based	O
)	O
are	O
most	O
valuable	O
when	O
screening	O
populations	O
of	O
cells	O
for	O
the	O
novel	O
genes	O
reflecting	O
potential	O
diagnostic	O
and	O
prognostic	O
markers	O
or	O
for	O
an	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
.	O

On	O
the	O
other	O
hand	O
,	O
custom	O
microarray	O
platforms	O
that	O
focus	O
on	O
specific	O
pre	O
-	O
selected	O
subset	O
of	O
genes	O
relevant	O
to	O
a	O
particular	O
field	O
of	O
investigation	O
can	O
be	O
less	O
costly	O
and	O
more	O
suitable	O
for	O
detection	O
of	O
smaller	O
gene	O
expression	O
changes	O
.	O

Microarray	O
technology	O
has	O
added	O
important	O
information	O
on	O
both	O
normal	O
development	O
and	O
pathological	O
changes	O
in	O
neurons	O
.	O

This	O
is	O
well	O
illustrated	O
by	O
multiple	O
studies	O
on	O
substantia	O
nigra	O
dopaminergic	O
neurons	O
,	O
which	O
degenerate	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
[	O
1	O
-	O
5	O
]	O
.	O

The	O
shortcomings	O
of	O
pharmacological	O
therapies	O
in	O
PD	O
have	O
stimulated	O
a	O
search	O
for	O
alternative	O
treatment	O
strategies	O
.	O

In	O
successful	O
cases	O
,	O
transplants	O
of	O
human	O
embryonic	O
mesencephalic	O
dopaminergic	O
neurons	O
can	O
both	O
restore	O
dopaminergic	O
neurotransmission	O
and	O
provide	O
some	O
symptomatic	O
relief	O
[	O
6	O
-	O
8	O
]	O
.	O

A	O
wider	O
application	O
of	O
neural	O
transplantation	O
in	O
PD	O
is	O
,	O
however	O
,	O
currently	O
not	O
feasible	O
due	O
to	O
the	O
unpredictable	O
and	O
variable	O
outcome	O
,	O
the	O
risks	O
of	O
unwanted	O
side	O
-	O
effects	O
(	O
dyskinesias	O
)	O
[	O
9,10	O
]	O
and	O
ethical	O
and	O
practical	O
problems	O
associated	O
with	O
using	O
donor	O
cells	O
obtained	O
from	O
aborted	O
embryos	O
and	O
fetuses	O
[	O
11,12	O
]	O
.	O

Human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
are	O
considered	O
a	O
promising	O
future	O
source	O
of	O
cells	O
for	O
cell	O
replacement	O
therapy	O
in	O
PD	O
and	O
other	O
neurological	O
conditions	O
[	O
13	O
]	O
.	O

They	O
could	O
constitute	O
a	O
virtually	O
infinite	O
source	O
of	O
self	O
-	O
renewing	O
cells	O
that	O
can	O
be	O
persuaded	O
to	O
differentiate	O
into	O
specific	O
types	O
of	O
neural	O
cells	O
,	O
including	O
dopaminergic	O
neurons	O
[	O
14	O
-	O
16	O
]	O
.	O

The	O
molecular	O
mechanisms	O
that	O
govern	O
development	O
of	O
cultured	O
hESCs	O
into	O
specific	O
types	O
of	O
neural	O
cells	O
are	O
not	O
fully	O
understood	O
.	O

To	O
promote	O
our	O
understanding	O
of	O
such	O
mechanisms	O
,	O
it	O
would	O
be	O
valuable	O
to	O
have	O
tools	O
that	O
readily	O
and	O
reproducibly	O
can	O
help	O
to	O
characterize	O
the	O
cells	O
as	O
they	O
differentiate	O
from	O
pluripotent	O
stem	O
cells	O
into	O
post	O
-	O
mitotic	O
neurons	O
.	O

This	O
important	O
issue	O
was	O
addressed	O
in	O
earlier	O
studies	O
by	O
Luo	O
et	O
al.	O
and	O
Yang	O
et	O
al.	O
,	O
who	O
designed	O
small	O
-	O
to	O
-	O
moderate	O
scale	O
custom	O
microarray	O
platforms	O
(	O
281	O
and	O
755	O
gene	O
targets	O
,	O
respectively	O
)	O
[	O
17,18	O
]	O
.	O

In	O
addition	O
SuperArray	O
Bioscience	O
Corporation	O
(	O
Frederick	O
,	O
MD	O
,	O
USA	O
)	O
have	O
manufactured	O
a	O
range	O
of	O
small	O
-	O
scale	O
arrays	O
(	O
263	O
gene	O
targets	O
for	O
human	O
array	O
;	O
[	O
19	O
]	O
)	O
.	O

We	O
sought	O
to	O
create	O
an	O
improved	O
and	O
updated	O
microarray	O
platform	O
for	O
hESC	O
/	O
neuronal	O
differentiation	O
-	O
oriented	O
gene	O
expression	O
studies	O
.	O

Therefore	O
,	O
we	O
generated	O
a	O
specialized	O
large	O
-	O
scale	O
DNA	O
microarray	O
platform	O
(	O
the	O
""""	O
NeuroStem	O
Chip	O
""""	O
)	O
that	O
has	O
over	O
1,300	O
pre	O
-	O
selected	O
gene	O
targets	O
and	O
multiple	O
controls	O
spotted	O
in	O
quadruplicates	O
(	O
~46,000	O
spots	O
total	O
)	O
.	O

Here	O
we	O
introduce	O
the	O
platform	O
and	O
the	O
advantages	O
it	O
can	O
offers	O
to	O
neuroscientists	O
and	O
stem	O
cell	O
biologists	O
:	O
particularly	O
,	O
in	O
the	O
niche	O
of	O
gene	O
expression	O
-	O
oriented	O
characterization	O
of	O
the	O
samples	O
using	O
an	O
assay	O
of	O
pre	O
-	O
selected	O
,	O
already	O
established	O
gene	O
targets	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
use	O
the	O
NeuroStem	O
Chip	O
to	O
characterize	O
an	O
undifferentiated	O
population	O
of	O
pluripotent	O
hESCs	O
(	O
cell	O
line	O
SA02	B
,	O
Cellartis	O
AB	O
,	O
GÃ¶teborg	O
,	O
Sweden	O
)	O
and	O
compare	O
the	O
gene	O
expression	O
in	O
those	O
cells	O
with	O
that	O
of	O
a	O
hESC	O
-	O
derived	O
cell	O
population	O
rich	O
in	O
neurons	O
,	O
including	O
tyrosine	O
hydroxylase	O
-	O
positive	O
dopaminergic	O
neurons	O
.	O

Stem	O
cells	O
have	O
unique	O
biological	O
characteristics	O
,	O
but	O
only	O
a	O
limited	O
number	O
of	O
genes	O
are	O
currently	O
recognized	O
as	O
established	O
stem	O
cell	O
markers	O
.	O

Examples	O
include	O
POU	O
domain	O
,	O
class	O
5	O
,	O
transcription	O
factor	O
1	O
(	O
Oct3	O
/	O
4	O
)	O
,	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
,	O
teratocarcinoma	O
-	O
derived	O
growth	O
factor	O
(	O
Tdgf1	O
)	O
,	O
Enk	O
-	O
pending	O
(	O
Nanog	O
)	O
,	O
undifferentiated	O
embryonic	O
cell	O
transcription	O
factor	O
1	O
(	O
Utf1	O
)	O
and	O
DNA	O
methyltransferase	O
3B	O
(	O
Dnmt3b	O
)	O
[	O
20	O
]	O
.	O

At	O
the	O
same	O
time	O
,	O
hundreds	O
of	O
genes	O
are	O
suggested	O
as	O
candidate	O
markers	O
for	O
""""	O
stemness	O
""""	O
,	O
but	O
their	O
coupling	O
to	O
the	O
undifferentiated	O
stem	O
cell	O
state	O
is	O
not	O
yet	O
fully	O
verified	O
[	O
21	O
]	O
.	O

The	O
concept	O
of	O
""""	O
stemness	O
""""	O
(	O
term	O
introduced	O
in	O
1986	O
by	O
Grossman	O
&	O
Levine	O
)	O
is	O
defined	O
as	O
""""	O
core	O
stem	O
cell	O
properties	O
that	O
underlie	O
self	O
-	O
renewal	O
and	O
the	O
ability	O
to	O
generate	O
differentiated	O
progeny	O
""""	O
[	O
22	O
]	O
.	O

Considering	O
the	O
complexity	O
of	O
the	O
processes	O
involved	O
,	O
stemness	O
can	O
hardly	O
be	O
ensured	O
by	O
co	O
-	O
operation	O
of	O
just	O
a	O
few	O
genes	O
.	O

Nevertheless	O
,	O
three	O
stemness	O
genes	O
(	O
namely	O
,	O
Oct3	O
/	O
4	O
,	O
Stat3	O
and	O
Nanog	O
)	O
are	O
considered	O
""""	O
master	O
"""-"	O
genes	O
that	O
control	O
the	O
self	O
-	O
renewing	O
process	O
[	O
23,24	O
]	O
.	O

Various	O
types	O
of	O
stem	O
cells	O
,	O
such	O
as	O
hematopoietic	O
,	O
mesenchymal	O
and	O
neural	O
(	O
HSCs	O
,	O
MSCs	O
and	O
NSCs	O
,	O
respectively	O
)	O
,	O
embryonic	O
germ	O
and	O
embryonic	O
carcinoma	O
cells	O
(	O
EGCs	O
and	O
ECCs	O
,	O
respectively	O
)	O
are	O
all	O
characterized	O
by	O
variations	O
in	O
gene	O
expression	O
profiles	O
,	O
and	O
only	O
a	O
few	O
gene	O
markers	O
are	O
associated	O
with	O
all	O
these	O
cell	O
types	O
[	O
25,26	O
]	O
.	O

We	O
have	O
aimed	O
to	O
embrace	O
the	O
most	O
comprehensive	O
set	O
of	O
those	O
genes	O
into	O
a	O
solitary	O
array	O
,	O
the	O
NeuroStem	O
Chip	O
.	O

Thereby	O
,	O
it	O
is	O
possible	O
to	O
employ	O
it	O
to	O
monitor	O
the	O
relative	O
expression	O
levels	O
of	O
numerous	O
known	O
and	O
candidate	O
stemness	O
genes	O
in	O
a	O
single	O
experiment	O
.	O

Similar	O
to	O
the	O
genetic	O
bases	O
underlying	O
stemness	O
,	O
cell	O
differentiation	O
is	O
associated	O
with	O
altered	O
expression	O
levels	O
of	O
certain	O
recognized	O
or	O
candidate	O
genes	O
[	O
25	O
]	O
.	O

We	O
therefore	O
incorporated	O
gene	O
markers	O
of	O
development	O
and	O
differentiation	O
in	O
general	O
,	O
and	O
that	O
of	O
neuronal	O
and	O
dopaminergic	O
differentiation	O
in	O
particular	O
,	O
into	O
the	O
NeuroStem	O
Chip	O
.	O

Examples	O
include	O
markers	O
for	O
the	O
processes	O
of	O
neuronal	O
maturation	O
,	O
axonal	O
branching	O
,	O
neural	O
/	O
neuronal	O
survival	O
,	O
etc	O
.	O

Finally	O
,	O
we	O
ensured	O
that	O
known	O
markers	O
for	O
specific	O
types	O
of	O
neurons	O
,	O
allowing	O
identification	O
of	O
individual	O
cell	O
types	O
,	O
were	O
present	O
on	O
the	O
chip	O
.	O

We	O
paid	O
special	O
attention	O
to	O
genes	O
associated	O
with	O
the	O
differentiation	O
and	O
maturation	O
of	O
dopaminergic	O
neurons	O
.	O

In	O
many	O
published	O
studies	O
,	O
the	O
expression	O
of	O
only	O
a	O
single	O
(	O
tyrosine	O
hydroxylase	O
,	O
TH	O
)	O
or	O
2â3	O
markers	O
for	O
dopaminergic	O
neurons	O
(	O
e.g.	O
amino	O
acid	O
decarboxylase	O
(	O
AADC	O
)	O
,	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
,	O
vesicular	O
monoamine	O
transporter	O
2	O
(	O
VMAT2	O
)	O
)	O
have	O
been	O
used	O
to	O
indicate	O
dopaminergic	O
identity	O
of	O
neurons	O
.	O

In	O
contrast	O
,	O
the	O
NeuroStem	O
Chip	O
includes	O
oligonucleotide	O
probes	O
for	O
88	O
genes	O
related	O
to	O
dopaminergic	O
neurons	O
,	O
thus	O
being	O
more	O
comprehensive	O
in	O
this	O
sense	O
,	O
compared	O
to	O
other	O
existing	O
microarray	O
platforms	O
,	O
including	O
focused	O
ones	O
[	O
17,18	O
]	O
.	O

Those	O
entries	O
encompass	O
recognized	O
and	O
candidate	O
markers	O
for	O
dopaminergic	O
neurons	O
(	O
mature	O
and	O
early	O
)	O
and	O
progenitors	O
,	O
as	O
well	O
as	O
markers	O
for	O
the	O
maturation	O
and	O
differentiation	O
of	O
the	O
latter	O
(	O
Table	O
1	O
)	O
.	O

Table	O
2	O
represents	O
conditional	O
functional	O
breakdown	O
of	O
genes	O
targeted	O
by	O
the	O
NeuroStem	O
microarray	O
platform	O
.	O

A	O
number	O
of	O
important	O
gene	O
groups	O
that	O
are	O
included	O
in	O
the	O
chip	O
are	O
not	O
mentioned	O
in	O
Table	O
2	O
.	O

Among	O
these	O
,	O
entries	O
related	O
to	O
Dickkopf	O
gene	O
family	O
,	O
galanin-	O
,	O
melatonin-	O
,	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
-	O
,	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
-	O
and	O
B	O
cell	O
leukemia	O
2	O
(	O
Bcl2	O
)	O
oncogene	O
-	O
related	O
are	O
present	O
.	O

Many	O
of	O
them	O
play	O
potentially	O
important	O
,	O
yet	O
undefined	O
,	O
roles	O
in	O
the	O
biology	O
of	O
stem	O
cells	O
.	O

Additionally	O
,	O
we	O
included	O
some	O
genes	O
implicated	O
in	O
disease	O
mechanisms	O
of	O
neurodegenerative	O
disorders	O
(	O
most	O
importantly	O
,	O
Parkinson	O
's	O
disease	O
and	O
Alzheimer	O
's	O
disease	O
)	O
in	O
the	O
chip	O
.	O

Furthermore	O
,	O
we	O
incorporated	O
a	O
number	O
of	O
markers	O
for	O
distinct	O
differentiation	O
pathways	O
(	O
e.g.	O
hematopoietic	O
and	O
pancreatic	O
)	O
and	O
cell	O
types	O
(	O
e.g.	O
cancer	O
subtypes	O
and	O
a	O
range	O
of	O
normal	O
cell	O
types	O
)	O
to	O
serve	O
as	O
essential	O
controls	O
.	O

Taken	O
together	O
,	O
we	O
believe	O
that	O
in	O
its	O
present	O
form	O
NeuroStem	O
Chip	O
represents	O
currently	O
most	O
comprehensive	O
gene	O
expression	O
platform	O
for	O
studies	O
on	O
stem	O
cells	O
,	O
neural	O
/	O
neuronal	O
differentiation	O
,	O
human	O
neurodegeneration	O
and	O
neuronal	O
survival	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
complete	O
layout	O
of	O
NeuroStem	O
Chip	O
will	O
be	O
disclosed	O
to	O
the	O
academic	O
community	O
,	O
upon	O
request	O
.	O

The	O
microarray	O
format	O
we	O
selected	O
relies	O
on	O
long	O
oligonucleotide	O
molecules	O
(	O
69â71	O
nucleotides	O
)	O
printed	O
over	O
a	O
solid	O
surface	O
.	O

We	O
spotted	O
the	O
synthesized	O
oligonucleotides	O
(	O
Operon	O
Biotechnologies	O
)	O
with	O
a	O
constant	O
concentration	O
across	O
the	O
slides	O
,	O
and	O
evaluated	O
the	O
quality	O
and	O
consistency	O
of	O
spotting	O
in	O
a	O
series	O
of	O
control	O
experiments	O
.	O

We	O
then	O
illustrated	O
the	O
utility	O
and	O
technical	O
reliability	O
of	O
the	O
NeuroStem	O
Chip	O
by	O
characterizing	O
the	O
gene	O
expression	O
profile	O
of	O
commonly	O
utilized	O
hESC	O
line	O
SA02	B
(	O
Sahlgrenska	B
2	I
;	O
[	O
27	O
]	O
)	O
,	O
including	O
(	O
i	O
)	O
undifferentiated	O
cells	O
and	O
(	O
ii	O
)	O
cells	O
committed	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
.	O

For	O
the	O
first	O
of	O
these	O
,	O
we	O
used	O
total	O
RNA	O
sample	O
purified	O
from	O
hESC	O
colonies	O
that	O
exhibited	O
morphology	O
consistent	O
with	O
cell	O
proliferation	O
and	O
the	O
absence	O
of	O
spontaneous	O
differentiation	O
(	O
Figure	O
1A	O
)	O
.	O

We	O
also	O
evaluated	O
the	O
expression	O
of	O
the	O
cell	O
cycle	O
marker	O
Ki67	O
and	O
the	O
pluripotency	O
marker	O
OCT3	O
/	O
4	O
in	O
the	O
sample	O
by	O
immunocytochemistry	O
(	O
Figure	O
1B	O
â	O
E	O
)	O
.	O

Co	O
-	O
culturing	O
of	O
ESCs	O
with	O
murine	O
stromal	O
cells	O
(	O
including	O
PA6	B
cell	O
line	O
)	O
rapidly	O
generates	O
dopaminergic	O
neurons	O
from	O
ESCs	O
by	O
an	O
unexplained	O
mechanism	O
termed	O
stromal	O
cell	O
-	O
derived	O
inducing	O
activity	O
(	O
SDIA	O
;	O
[	O
28,29	O
]	O
)	O
.	O

We	O
therefore	O
committed	O
hESCs	O
toward	O
the	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
PA6	B
cells	O
for	O
16	O
days	O
,	O
resulting	O
in	O
appearance	O
of	O
cells	O
positive	O
for	O
early	O
and	O
late	O
neuronal	O
markers	O
,	O
including	O
nestin	O
,	O
Î²	O
-	O
III	O
-	O
tubulin	O
,	O
and	O
TH	O
,	O
the	O
established	O
marker	O
of	O
dopaminergic	O
neurons	O
(	O
Figure	O
2	O
)	O
.	O

To	O
verify	O
the	O
expression	O
of	O
some	O
key	O
stem	O
cell-	O
and	O
neural	O
phenotype	O
-	O
associated	O
genes	O
we	O
performed	O
RT	O
-	O
PCR	O
comparing	O
RNA	O
samples	O
from	O
the	O
undifferentiated	O
hESCs	O
with	O
hESCs	O
of	O
the	O
same	O
line	O
differentiated	O
toward	O
neuronal	O
/	O
dopaminergic	O
pathway	O
,	O
as	O
described	O
above	O
.	O

The	O
expression	O
profile	O
outlined	O
by	O
RT	O
-	O
PCR	O
confirmed	O
the	O
identity	O
of	O
the	O
sample	O
used	O
(	O
Figure	O
3	O
)	O
.	O

After	O
performing	O
RNA	O
integrity	O
tests	O
,	O
we	O
incorporated	O
fluorescent	O
labels	O
to	O
the	O
amplified	O
RNA	O
samples	O
from	O
hESCs	O
(	O
Cyanine	O
3-CTP	O
(	O
Cy3	O
)	O
and	O
Cyanine	O
5-CTP	O
(	O
Cy5	O
)	O
)	O
,	O
hESC	O
-	O
derived	O
cells	O
containing	O
TH	O
-	O
positive	O
neurons	O
(	O
Cy3	O
and	O
Cy5	O
)	O
and	O
human	O
universal	O
reference	O
RNA	O
(	O
Cy5	O
)	O
,	O
and	O
hybridized	O
aliquots	O
with	O
NeuroStem	O
microarray	O
slides	O
using	O
the	O
following	O
conditions	O
:	O
hESC	O
vs.	O
reference	O
,	O
Cy3	O
:	O
Cy5	O
=	O
(	O
i	O
)	O
20:10	O
pmol	O
,	O
and	O
(	O
ii	O
)	O
10:5	O
pmol	O
;	O
and	O
hESC	O
vs.	O
hESC	O
-	O
derived	O
cells	O
,	O
Cy3	O
:	O
Cy5	O
=	O
(	O
iii	O
)	O
30:20	O
pmol	O
,	O
respectively	O
.	O

Universal	O
reference	O
RNA	O
has	O
been	O
previously	O
established	O
as	O
a	O
standard	O
reference	O
material	O
for	O
microarray	O
experiments	O
,	O
proving	O
an	O
ability	O
to	O
effectively	O
hybridize	O
to	O
a	O
large	O
fraction	O
of	O
microarray	O
spots	O
[	O
30	O
]	O
.	O

We	O
performed	O
two	O
-	O
color	O
hybridizations	O
(	O
e.g.	O
for	O
the	O
experiment	O
vs.	O
reference	O
)	O
following	O
an	O
established	O
protocol	O
[	O
31	O
]	O
,	O
and	O
included	O
dye	O
-	O
flip	O
technical	O
replicates	O
in	O
the	O
analysis	O
(	O
Figure	O
4	O
)	O
.	O

Using	O
the	O
online	O
software	O
program	O
BASE	O
[	O
32	O
]	O
we	O
sequentially	O
filtered	O
the	O
data	O
by	O
background	O
subtraction	O
,	O
negative	O
flagging	O
,	O
negative	O
intensities	O
and	O
for	O
inconsistent	O
data	O
amongst	O
replicates	O
[	O
33	O
]	O
.	O

Figure	O
5A	O
shows	O
a	O
comparison	O
of	O
the	O
spot	O
intensities	O
prior	O
to	O
normalization	O
(	O
M	O
versus	O
A	O
plot	O
)	O
,	O
with	O
the	O
Log2	O
of	O
the	O
expression	O
ratio	O
between	O
Cy3	O
/	O
Cy5	O
being	O
plotted	O
as	O
a	O
function	O
of	O
the	O
log10	O
of	O
the	O
mean	O
of	O
the	O
total	O
expression	O
intensities	O
for	O
Cy3	O
and	O
Cy5	O
channels	O
.	O

The	O
deviation	O
of	O
the	O
line	O
from	O
zero	O
revealed	O
a	O
need	O
for	O
normalization	O
,	O
so	O
prior	O
to	O
data	O
analyses	O
we	O
normalized	O
signals	O
using	O
a	O
locally	O
weighted	O
scatterplot	O
-	O
smoothing	O
regression	O
(	O
LOWESS	O
)	O
algorithm	O
(	O
Figure	O
5A	O
â	O
B	O
;	O
fitted	O
line	O
)	O
implemented	O
in	O
BASE	O
.	O

Since	O
the	O
reproducibility	O
of	O
two	O
-	O
color	O
microarray	O
gene	O
expression	O
data	O
is	O
critically	O
important	O
,	O
we	O
calculated	O
Pearson	O
correlation	O
coefficients	O
of	O
the	O
reporters	O
present	O
in	O
the	O
filtered	O
database	O
comparing	O
the	O
average	O
expression	O
ratios	O
(	O
7005	O
for	O
hESCs	O
vs.	O
universal	O
reference	O
;	O
6947	O
for	O
undifferentiated	O
vs.	O
neuronal	O
/	O
dopaminergic	O
lineage	O
-	O
committed	O
hESCs	O
)	O
.	O

Results	O
obtained	O
revealed	O
that	O
data	O
were	O
consistent	O
across	O
technical	O
replicates	O
(	O
dye	O
-	O
swap	O
and	O
amount	O
of	O
loaded	O
material	O
)	O
,	O
showing	O
general	O
high	O
reproducibility	O
:	O
e.g.	O
,	O
correlation	O
coefficients	O
were	O
greater	O
than	O
0.96	O
for	O
technical	O
replicates	O
and	O
0.78	O
for	O
dye	O
-	O
swapping	O
samples	O
in	O
hESCs	O
vs.	O
universal	O
reference	O
hybridizations	O
(	O
Table	O
3	O
)	O
.	O

To	O
detect	O
genes	O
with	O
high	O
expression	O
levels	O
in	O
hESC	O
samples	O
,	O
we	O
filtered	O
data	O
for	O
intensity	O
values	O
>	O
100	O
in	O
the	O
hESC	O
sample	O
and	O
performed	O
clustering	O
analysis	O
using	O
the	O
TIGR	O
MultiExperiment	O
Viewer	O
(	O
MEV	O
;	O
[	O
34	O
]	O
)	O
.	O

To	O
visualize	O
variations	O
of	O
spot	O
/	O
reporter	O
per	O
technical	O
replicate	O
,	O
hierarchical	O
clustering	O
was	O
performed	O
by	O
K	O
-	O
means	O
classifier	O
based	O
on	O
the	O
linear	O
-	O
correlation	O
-	O
based	O
distance	O
(	O
Pearson	O
,	O
centred	O
)	O
method	O
.	O

The	O
optimal	O
number	O
of	O
clusters	O
was	O
determined	O
empirically	O
to	O
produce	O
the	O
most	O
balanced	O
ratio	O
of	O
entries	O
to	O
cluster	O
of	O
highly	O
expressed	O
genes	O
.	O

A	O
cluster	O
of	O
101	O
genes	O
up	O
-	O
regulated	O
in	O
the	O
hESC	O
sample	O
[	O
see	O
Additional	O
file	O
1	O
]	O
,	O
was	O
plotted	O
in	O
a	O
centroid	O
graph	O
(	O
Figure	O
5C	O
)	O
;	O
the	O
variation	O
across	O
technical	O
replicates	O
was	O
low	O
.	O

We	O
merged	O
technical	O
replicates	O
to	O
generate	O
a	O
list	O
of	O
the	O
most	O
up	O
-	O
regulated	O
genes	O
expressed	O
in	O
the	O
hESC	O
sample	O
compared	O
to	O
the	O
universal	O
reference	O
RNA	O
(	O
Table	O
4	O
)	O
.	O

Standard	O
error	O
of	O
the	O
mean	O
expressed	O
as	O
percentage	O
was	O
calculated	O
for	O
the	O
4	O
technical	O
replicates	O
,	O
and	O
was	O
6.7	O
%	O
for	O
the	O
top	O
25	O
genes	O
up	O
-	O
regulated	O
in	O
hESC	O
samples	O
,	O
compared	O
to	O
universal	O
reference	O
RNA	O
.	O

We	O
performed	O
the	O
analysis	O
of	O
microarray	O
data	O
,	O
as	O
described	O
in	O
the	O
Methods	O
,	O
and	O
spot	O
error	O
values	O
were	O
generally	O
in	O
the	O
lower	O
range	O
,	O
indicating	O
high	O
stringency	O
of	O
the	O
signals	O
and	O
low	O
variance	O
.	O

As	O
seen	O
in	O
Table	O
4	O
and	O
Table	O
5	O
,	O
the	O
NeuroStem	O
Chip	O
identified	O
numerous	O
genes	O
associated	O
with	O
stem	O
cells	O
.	O

In	O
particular	O
,	O
homeo	O
box	O
expressed	O
in	O
ES	O
cells	O
1	O
(	O
Hesx1	O
)	O
gene	O
was	O
identified	O
as	O
the	O
most	O
up	O
-	O
regulated	O
in	O
the	O
ES	O
cell	O
preparation	O
,	O
compared	O
to	O
universal	O
reference	O
RNA	O
.	O

Highly	O
expressed	O
in	O
pluripotent	O
ESCs	O
,	O
Hesx1	O
expression	O
is	O
down	O
-	O
regulated	O
upon	O
embryonic	O
stem	O
cell	O
differentiation	O
[	O
35,36	O
]	O
,	O
as	O
also	O
clearly	O
seen	O
in	O
differentiation	O
experiment	O
of	O
our	O
own	O
(	O
Table	O
4	O
)	O
.	O

Similarly	O
,	O
Gremlin	O
1	O
homolog	O
,	O
cysteine	O
knot	O
superfamily	O
gene	O
(	O
Grem1	O
,	O
also	O
known	O
as	O
Cktsf1b1	O
and	O
Dand2	O
)	O
is	O
a	O
recognized	O
factor	O
of	O
cell	O
-	O
fate	O
determination	O
of	O
ESCs	O
[	O
37	O
]	O
.	O

Many	O
more	O
genes	O
highly	O
up	O
-	O
regulated	O
in	O
the	O
hESC	O
sample	O
in	O
comparison	O
with	O
universal	O
reference	O
RNA	O
are	O
associated	O
with	O
stem	O
cells	O
:	O
further	O
examples	O
include	O
Gap	O
junction	O
protein	O
Î±1	O
(	O
Gja1	O
)	O
and	O
Zic	O
family	O
member	O
3	O
heterotaxy	O
1	O
(	O
Zic3	O
)	O
(	O
Table	O
4	O
)	O
[	O
20	O
]	O
.	O

The	O
expression	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
(	O
Fgfr2	O
)	O
is	O
of	O
particular	O
interest	O
.	O

Basic	O
fibroblast	O
growth	O
factor	O
(	O
FGF2	O
,	O
bFGF	O
)	O
supports	O
hESC	O
proliferation	O
and	O
their	O
ability	O
to	O
maintain	O
undifferentiated	O
phenotype	O
when	O
cultured	O
in	O
vitro	O
[	O
38,39	O
]	O
.	O

Moreover	O
,	O
in	O
some	O
hESC	O
lines	O
a	O
very	O
high	O
concentration	O
of	O
FGF2	O
could	O
substitute	O
for	O
the	O
need	O
of	O
feeder	O
cells	O
[	O
40	O
]	O
.	O

At	O
the	O
same	O
time	O
,	O
genes	O
listed	O
in	O
Table	O
4	O
represent	O
the	O
most	O
highly	O
up	O
-	O
regulated	O
entries	O
in	O
a	O
relatively	O
limited	O
group	O
of	O
genes	O
(	O
Figure	O
5C	O
)	O
.	O

Many	O
other	O
genes	O
involved	O
in	O
maintenance	O
of	O
ESC	O
phenotype	O
(	O
i.e.	O
established	O
or	O
candidate	O
markers	O
of	O
stem	O
cells	O
)	O
have	O
lower	O
levels	O
of	O
expression	O
(	O
Table	O
5	O
)	O
.	O

Examples	O
include	O
undifferentiated	O
embryonic	O
cell	O
transcription	O
factor	O
1	O
(	O
Utf1	O
)	O
,	O
DNA	O
methyltransferase	O
3B	O
(	O
Dnmt3b	O
)	O
,	O
developmental	O
pluripotency	O
associated	O
4	O
(	O
Dppa4	O
,	O
a	O
newly	O
established	O
pluripotency	O
marker	O
[	O
41	O
]	O
)	O
and	O
numerous	O
candidate	O
markers	O
of	O
""""	O
stemness	O
""""	O
:	O
e.g.	O
genes	O
for	O
KIAA1573	O
protein	O
,	O
forkhead	O
box	O
O1A	O
(	O
Foxo1a	O
)	O
,	O
high	O
-	O
mobility	O
group	O
box	O
1	O
(	O
Hmgb1	O
)	O
,	O
C	O
-	O
terminal	O
binding	O
protein	O
2	O
(	O
Ctbp2	O
)	O
and	O
left	O
-	O
right	O
determination	O
factor	O
1	O
(	O
Lefty1	O
)	O
,	O
as	O
well	O
as	O
others	O
.	O

For	O
numerous	O
established	O
or	O
candidate	O
markers	O
of	O
stem	O
cells	O
the	O
expression	O
levels	O
were	O
not	O
considerably	O
higher	O
(	O
Log2	O
ratio	O
<	O
1	O
)	O
in	O
the	O
hESC	O
sample	O
compared	O
to	O
the	O
universal	O
reference	O
RNA	O
.	O

For	O
example	O
,	O
the	O
expression	O
of	O
Nanog	O
,	O
DNA	O
(	O
cytosine-5-	O
)	O
-methyltransferase	O
3Î±	O
(	O
Dnmt3a	O
)	O
,	O
MutS	O
homolog	O
2	O
,	O
colon	O
cancer	O
,	O
nonpolyposis	O
type	O
1	O
(	O
E.	O
coli	O
)	O
(	O
Msh2	O
)	O
,	O
Thy-1	O
cell	O
surface	O
antigen	O
(	O
Thy1	O
)	O
,	O
high	O
-	O
mobility	O
group	O
box	O
2	O
(	O
Hmgb2	O
)	O
,	O
transcription	O
factor	O
3	O
(	O
Tcf3	O
)	O
,	O
Nanos	O
homolog	O
1	O
(	O
Nanos1	O
)	O
,	O
MyoD	O
family	O
inhibitor	O
(	O
Mdfi	O
)	O
,	O
Calumenin	O
(	O
Calu	O
)	O
and	O
soluble	O
thymidine	O
kinase	O
1	O
(	O
Tk1	O
)	O
was	O
detected	O
in	O
hES	O
SA02	B
cells	O
with	O
Log2	O
ratio	O
value	O
<	O
1	O
.	O

Expression	O
levels	O
of	O
those	O
genes	O
range	O
from	O
being	O
inconsiderably	O
higher	O
to	O
nearly	O
equal	O
to	O
that	O
in	O
universal	O
reference	O
RNA	O
sample	O
.	O

We	O
believe	O
that	O
those	O
findings	O
could	O
be	O
explained	O
by	O
cellular	O
composition	O
of	O
human	O
universal	O
reference	O
RNA	O
sample	O
[	O
42	O
]	O
,	O
which	O
includes	O
pooled	O
RNA	O
samples	O
from	O
proliferating	O
cells	O
(	O
e.g.	O
,	O
skin	O
and	O
testis	O
cell	O
lines	O
)	O
.	O

Thus	O
,	O
the	O
relative	O
difference	O
between	O
gene	O
expression	O
of	O
certain	O
markers	O
of	O
stem	O
cells	O
in	O
undifferentiated	O
hESCs	O
and	O
universal	O
reference	O
RNA	O
is	O
naturally	O
decreased	O
.	O

Taken	O
together	O
,	O
the	O
gene	O
expression	O
signature	O
of	O
hES	O
SA02	B
cell	O
line	O
profiled	O
by	O
NeuroStem	O
Chip	O
is	O
indeed	O
characteristic	O
for	O
pluripotent	O
stem	O
cells	O
,	O
providing	O
proof	O
-	O
of	O
-	O
concept	O
.	O

Notably	O
,	O
comparison	O
of	O
expression	O
profiles	O
of	O
undifferentiated	O
hESCs	O
and	O
hESC	O
-	O
derived	O
cells	O
committed	O
toward	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
SDIA	O
for	O
16	O
days	O
have	O
revealed	O
that	O
many	O
of	O
the	O
stem	O
cell	O
marker	O
genes	O
mentioned	O
above	O
were	O
down	O
-	O
regulated	O
in	O
differentiation	O
(	O
Table	O
5	O
)	O
.	O

Expectedly	O
,	O
Hesx1	O
,	O
Grem1	O
,	O
Dnmt3b	O
,	O
Utf1	O
and	O
Nanog	O
could	O
be	O
listed	O
among	O
these	O
.	O

At	O
the	O
same	O
time	O
,	O
numerous	O
other	O
genes	O
,	O
including	O
Pitx2	O
,	O
Dlk1	O
and	O
Msx1	O
were	O
up	O
-	O
regulated	O
in	O
the	O
latter	O
sample	O
(	O
[	O
see	O
Additional	O
file	O
2	O
]	O
,	O
Figure	O
3	O
)	O
.	O

Table	O
1	O
lists	O
24	O
dopaminergic	O
system	O
-	O
related	O
entries	O
(	O
e.g.	O
,	O
Ptx3	O
,	O
Th	O
,	O
Lhx1	O
)	O
with	O
gene	O
expression	O
up	O
-	O
regulated	O
by	O
Day	O
16	O
of	O
hESC	O
differentiation	O
protocol	O
;	O
few	O
more	O
genes	O
have	O
demonstrated	O
less	O
prominent	O
up	O
-	O
regulation	O
(	O
Log2	O
ratio	O
values	O
in	O
the	O
range	O
of	O
0.7	O
/	O
0.97â1.0	O
)	O
.	O

The	O
gene	O
expression	O
profiles	O
generated	O
are	O
therefore	O
consistent	O
with	O
the	O
results	O
of	O
earlier	O
studies	O
utilizing	O
hSC	O
-	O
derived	O
samples	O
with	O
similar	O
characteristics	O
[	O
43,44	O
]	O
.	O

Diversity	O
of	O
NeuroStem	O
Chip	O
entries	O
responsive	O
to	O
hESC	O
commitment	O
toward	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
clearly	O
illustrates	O
the	O
complexity	O
of	O
that	O
pathway	O
.	O

The	O
cell	O
population	O
obtained	O
after	O
16	O
day	O
exposure	O
to	O
SDIA	O
is	O
highly	O
heterogeneous	O
.	O

Only	O
around	O
0.2	O
%	O
of	O
the	O
cells	O
are	O
TH	O
-	O
positive	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

This	O
heterogeneity	O
,	O
with	O
an	O
apparent	O
presence	O
of	O
residual	O
pluripotent	O
cells	O
explains	O
the	O
presence	O
of	O
stem	O
cell	O
marker	O
genes	O
,	O
including	O
homeobox	O
transcription	O
factor	O
Nanog	O
,	O
as	O
revealed	O
by	O
RT	O
-	O
PCR	O
data	O
(	O
Figure	O
3	O
)	O
.	O

It	O
would	O
be	O
therefore	O
impossible	O
to	O
apply	O
the	O
platform	O
to	O
identify	O
novel	O
genes	O
associated	O
with	O
the	O
process	O
of	O
differentiation	O
;	O
for	O
that	O
application	O
,	O
the	O
genome	O
-	O
scale	O
microarray	O
platforms	O
(	O
e.g.	O
,	O
Affymetrix	O
)	O
are	O
clearly	O
superior	O
.	O

Nevertheless	O
,	O
being	O
based	O
upon	O
a	O
moderate	O
assay	O
of	O
pre	O
-	O
selected	O
specific	O
gene	O
targets	O
,	O
the	O
comparative	O
analysis	O
of	O
microarray	O
data	O
derived	O
from	O
undifferentiated	O
and	O
dopaminergic	O
differentiate	O
pathway	O
-	O
committed	O
hESCs	O
provides	O
a	O
valuable	O
cross	O
-	O
cut	O
of	O
complex	O
relationship	O
between	O
factors	O
driving	O
or	O
indicative	O
to	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

RT	O
-	O
PCR	O
analyses	O
have	O
validated	O
the	O
overall	O
reliability	O
of	O
NeuroStem	O
microarray	O
platform	O
:	O
all	O
of	O
the	O
entries	O
detected	O
in	O
the	O
hybridization	O
experiments	O
have	O
demonstrated	O
similar	O
trends	O
when	O
analyzed	O
by	O
RT	O
-	O
PCR	O
means	O
(	O
Figure	O
3	O
)	O
.	O

Those	O
entries	O
include	O
Sox2	O
,	O
En1	O
and	O
Nanog	O
(	O
ratio	O
of	O
differentiated	O
/	O
undifferentiated	O
hESC	O
sample	O
normalized	O
spot	O
intensity	O
<	O
0.75	O
,	O
down	O
-	O
regulated	O
)	O
,	O
Gadph	O
,	O
Aldh1a1	O
,	O
Sdha	O
,	O
Tubb	O
and	O
Nestin	O
(	O
ratio	O
.1.0	O
,	O
unchanged	O
)	O
,	O
Actb	O
,	O
Th	O
,	O
Msx1	O
and	O
Pitx2	O
(	O
ratio	O
>	O
1.25	O
,	O
up	O
-	O
regulated	O
)	O
.	O

Some	O
of	O
the	O
housekeeping	O
genes	O
(	O
Gapdh	O
,	O
Sdha	O
,	O
Tubb	O
,	O
Actb	O
)	O
have	O
somewhat	O
different	O
expression	O
in	O
undifferentiated	O
vs.	O
differentiated	O
cells	O
,	O
consistent	O
with	O
previous	O
reports	O
on	O
certain	O
established	O
housekeeping	O
genes	O
(	O
including	O
Gapdh	O
)	O
being	O
variable	O
in	O
human	O
samples	O
[	O
45	O
]	O
.	O

Importantly	O
,	O
all	O
the	O
observed	O
gene	O
expression	O
trends	O
were	O
similar	O
in	O
both	O
microarray	O
and	O
RT	O
-	O
PCR	O
.	O

Our	O
experiment	O
therefore	O
confirms	O
that	O
the	O
NeuroStem	O
Chip	O
microarray	O
platform	O
can	O
still	O
identify	O
gene	O
expression	O
changes	O
related	O
to	O
early	O
stages	O
of	O
differentiation	O
of	O
hESC	O
into	O
dopaminergic	O
neurons	O
.	O

Recent	O
technological	O
advances	O
have	O
led	O
to	O
DNA	O
microarrays	O
which	O
contain	O
over	O
hundred	O
thousand	O
of	O
spots	O
of	O
DNA	O
material	O
,	O
reaching	O
a	O
truly	O
genomic	O
scale	O
.	O

Highly	O
specialized	O
DNA	O
microarrays	O
of	O
smaller	O
scale	O
(	O
e.g.	O
the	O
NeuroStem	O
Chip	O
)	O
still	O
have	O
an	O
important	O
role	O
in	O
the	O
directed	O
studies	O
in	O
particular	O
fields	O
.	O

Since	O
they	O
are	O
significantly	O
less	O
expensive	O
,	O
compared	O
to	O
many	O
recognized	O
large	O
-	O
scale	O
platforms	O
(	O
e.g.	O
Affymetrix	O
Human	O
Genome	O
platforms	O
)	O
,	O
they	O
have	O
a	O
clear	O
advantage	O
in	O
routine	O
work	O
involving	O
samples	O
from	O
,	O
e.g.	O
,	O
multiple	O
cell	O
culture	O
conditions	O
.	O

While	O
there	O
is	O
a	O
risk	O
that	O
one	O
will	O
miss	O
out	O
on	O
changes	O
in	O
genes	O
previously	O
not	O
believed	O
to	O
be	O
relevant	O
to	O
neural	O
differentiation	O
,	O
the	O
restricted	O
number	O
of	O
genes	O
in	O
the	O
NeuroStem	O
Chip	O
also	O
simplifies	O
analysis	O
and	O
adds	O
power	O
.	O

NeuroStem	O
Chip	O
is	O
comparable	O
to	O
other	O
stem	O
cell	O
-	O
related	O
focused	O
microarray	O
platforms	O
in	O
regards	O
to	O
manufacturing	O
costs	O
and	O
technical	O
simplicity	O
of	O
the	O
recommended	O
hybridization	O
protocols	O
.	O

At	O
the	O
same	O
time	O
,	O
it	O
currently	O
implies	O
an	O
advantage	O
in	O
both	O
the	O
scale	O
and	O
the	O
spectrum	O
of	O
pre	O
-	O
selected	O
,	O
specific	O
gene	O
targets	O
assayed	O
.	O

Some	O
suggested	O
areas	O
of	O
application	O
for	O
NeuroStem	O
microarray	O
platform	O
could	O
be	O
the	O
following	O
:	O
(	O
i	O
)	O
characterization	O
of	O
the	O
expression	O
of	O
established	O
,	O
pre	O
-	O
selected	O
gene	O
targets	O
in	O
human	O
stem	O
cell	O
(	O
hSC	O
)	O
lines	O
,	O
including	O
newly	O
derived	O
ones	O
,	O
(	O
ii	O
)	O
longitudinal	O
quality	O
control	O
for	O
maintained	O
hSC	O
populations	O
,	O
(	O
iii	O
)	O
following	O
gene	O
expression	O
changes	O
during	O
differentiation	O
under	O
defined	O
cell	O
culture	O
conditions	O
,	O
and	O
(	O
iv	O
)	O
confirming	O
the	O
success	O
of	O
differentiation	O
into	O
specific	O
neuronal	O
subtypes	O
.	O

In	O
addition	O
,	O
the	O
NeuroStem	O
Chip	O
can	O
be	O
used	O
to	O
characterize	O
gene	O
changes	O
in	O
intracerebral	O
grafts	O
of	O
human	O
cells	O
,	O
even	O
when	O
they	O
are	O
transplanted	O
into	O
experimental	O
animals	O
.	O

We	O
specifically	O
wish	O
to	O
stress	O
that	O
we	O
are	O
about	O
to	O
make	O
the	O
NeuroStem	O
Chip	O
available	O
at	O
a	O
non	O
-	O
profit	O
cost	O
to	O
the	O
research	O
community	O
.	O

We	O
believe	O
it	O
has	O
the	O
potential	O
to	O
become	O
an	O
important	O
screening	O
tool	O
in	O
the	O
expanding	O
field	O
of	O
hSC	O
studies	O
in	O
application	O
to	O
neurological	O
/	O
neurodegenerative	O
disorders	O
.	O

Human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
culturesUndifferentiated	O
hESCs	O
of	O
SA02	B
(	O
Sahlgrenska	B
2	I
)	O
line	O
(	O
Cellartis	O
AB	O
,	O
GÃ¶teborg	O
,	O
Sweden	O
;	O
see	O
NIH	O
Human	O
Embryonic	O
Stem	O
Cell	O
Registry	O
at	O
[	O
46	O
]	O
)	O
were	O
maintained	O
over	O
a	O
monolayer	O
of	O
human	O
""""	O
feeder	O
cells	O
""""	O
(	O
hFCs	O
;	O
human	O
foreskin	O
fibroblasts	O
,	O
ATCC	O
;	O
cell	O
line	O
CCD-1112Sk	B
)	O
.	O

Feeder	O
cells	O
were	O
grown	O
in	O
hFC	O
medium	O
(	O
Iscove	O
's	O
modified	O
Dulbecco	O
's	O
medium	O
(	O
IMDM	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
FCS	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
USA	O
)	O
and	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
mix	O
)	O
for	O
11	O
passages	O
.	O

One	O
day	O
prior	O
to	O
hESC	O
plating	O
,	O
hFC	O
medium	O
was	O
washed	O
away	O
from	O
the	O
hFCs	O
,	O
the	O
latter	O
were	O
resuspended	O
in	O
a	O
hESC	O
proliferation	O
medium	O
(	O
VitroHES	O
media	O
(	O
Vitrolife	O
AB	O
,	O
Sweden	O
)	O
supplemented	O
with	O
4	O
ng	O
/	O
ml	O
human	O
recombinant	O
basic	O
FGF	O
(	O
hrbFGF	O
,	O
Biosource	O
International	O
,	O
USA	O
)	O
and	O
plated	O
in	O
a	O
central	O
ring	O
of	O
gelatinized	O
in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
dishes	O
with	O
a	O
cell	O
density	O
of	O
120,000	O
cells	O
/	O
dish	O
.	O

The	O
outer	O
rings	O
of	O
the	O
IVF	O
dishes	O
were	O
filled	O
with	O
Dulbecco	O
's	O
modified	O
Eagle	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
mix	O
.	O

One	O
half	O
of	O
the	O
culture	O
medium	O
was	O
replaced	O
every	O
other	O
day	O
.	O

The	O
cells	O
were	O
maintained	O
at	O
37	O
Â°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
95	O
%	O
humidity	O
settings	O
.	O

Every	O
6	O
days	O
,	O
fragments	O
of	O
the	O
hESC	O
colonies	O
(	O
around	O
10â14	O
colonies	O
per	O
dish	O
,	O
measuring	O
around	O
0.015	O
Ã	O
0.015	O
mm	O
)	O
that	O
had	O
an	O
unaltered	O
morphology	O
(	O
indicating	O
lack	O
of	O
spontaneous	O
differentiation	O
)	O
were	O
mechanically	O
cut	O
from	O
dishes	O
using	O
stem	O
cell	O
knives	O
/	O
transfer	O
pipettes	O
(	O
SweMed	O
Lab	O
International	O
AB	O
,	O
Sweden	O
)	O
and	O
then	O
plated	O
on	O
fresh	O
hFCs	O
.	O

Commitment	O
of	O
hESCs	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathwayCo	O
-	O
culturing	O
with	O
the	O
PA6	B
stromal	O
cell	O
line	O
(	O
MC3T3-G2	O
/	O
Pa6	O
,	O
from	O
RIKEN	O
Cell	O
Bank	O
Japan	O
(	O
RCB	O
1127	O
)	O
,	O
derived	O
from	O
newborn	O
mouse	O
calvaria	O
rapidly	O
generates	O
high	O
numbers	O
of	O
DA	O
neurons	O
from	O
mouse	O
and	O
monkey	O
ESCs	O
by	O
an	O
unknown	O
mechanism	O
named	O
stromal	O
-	O
derived	O
inducing	O
activity	O
(	O
SDIA	O
;	O
[	O
28,29	O
]	O
)	O
.	O

For	O
differentiation	O
experiments	O
,	O
PA6	B
cells	O
were	O
plated	O
on	O
gelatine	O
-	O
coated	O
T25	O
flasks	O
at	O
16	O
Ã	O
103	O
cells	O
/	O
cm2	O
(	O
400,000	O
cells	O
/	O
flask	O
)	O
density	O
2	O
days	O
prior	O
to	O
introducing	O
hESCs	O
into	O
the	O
co	O
-	O
culture	O
and	O
cultured	O
at	O
PA6	B
culturing	O
media	O
(	O
containing	O
minimum	O
essential	O
medium	O
alpha	O
(	O
Î±	O
-	O
MEM	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
and	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
)	O
.	O

Alternatively	O
,	O
PA6	B
cells	O
were	O
plated	O
over	O
Type	O
I	O
collagen	O
-	O
coated	O
glass	O
cover	O
-	O
slips	O
placed	O
in	O
wells	O
of	O
4-well	O
-	O
plates	O
(	O
50,000	O
cells	O
/	O
well	O
,	O
for	O
immunocytochemical	O
(	O
ICC	O
)	O
analysis	O
)	O
.	O

Three	O
hours	O
prior	O
to	O
initiation	O
of	O
co	O
-	O
culture	O
,	O
PA6	B
cells	O
were	O
rinsed	O
3	O
times	O
with	O
PBS	O
and	O
media	O
was	O
replaced	O
with	O
co	O
-	O
culture	O
media	O
(	O
Glasgow	O
's	O
modified	O
Eagle	O
's	O
media	O
(	O
G	O
-	O
MEM	O
)	O
supplemented	O
with	O
8	O
%	O
knock	O
-	O
out	O
serum	O
replacement	O
(	O
KSR	O
)	O
,	O
2	O
mM	O
glutamine	O
,	O
0.1	O
mM	O
non	O
-	O
essential	O
amino	O
-	O
acids	O
(	O
NEAA	O
)	O
,	O
1	O
mM	O
pyruvate	O
,	O
0.1	O
mM	O
Î²	O
-	O
mercaptoethanol	O
(	O
Î²ME	O
)	O
and	O
4	O
ng	O
/	O
Î¼l	O
bFGF	O
)	O
.	O

Fragments	O
of	O
hESC	O
colonies	O
(	O
80â90	O
per	O
flask	O
;	O
4â5	O
per	O
well	O
of	O
4-well	O
-	O
plate	O
)	O
presenting	O
undifferentiated	O
morphology	O
were	O
manually	O
passaged	O
onto	O
the	O
confluent	O
PA6	B
monolayer	O
and	O
cell	O
co	O
-	O
cultures	O
were	O
maintained	O
at	O
37	O
Â°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
95	O
%	O
humidity	O
settings	O
.	O

One	O
half	O
of	O
the	O
co	O
-	O
culture	O
medium	O
was	O
replaced	O
every	O
other	O
day	O
for	O
first	O
10	O
days	O
,	O
and	O
daily	O
onwards	O
.	O

Characterization	O
of	O
hESCs	O
and	O
hESC	O
-	O
derived	O
cells	O
by	O
immunocytochemistry	O
(	O
ICC	O
)	O
and	O
RT	O
-	O
PCRIVF	O
dishes	O
with	O
hESCs	O
grown	O
atop	O
hFCs	O
and	O
4-well	O
plate	O
dishes	O
with	O
hESCs	O
growing	O
atop	O
PA6	B
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
for	O
15	O
minutes	O
at	O
the	O
day	O
of	O
passage	O
/	O
harvest	O
(	O
Day	O
6	O
of	O
hESC	O
/	O
hFC	O
co	O
-	O
culturing	O
)	O
and	O
Day	O
16	O
of	O
co	O
-	O
culturing	O
with	O
PA6	B
cells	O
,	O
respectively	O
.	O

Cells	O
were	O
pre	O
-	O
incubated	O
with	O
blocking	O
solution	O
containing	O
PBS	O
,	O
0.5	O
%	O
Triton	O
X-100	O
and	O
5	O
%	O
of	O
donkey	O
serum	O
.	O

They	O
were	O
then	O
incubated	O
with	O
primary	O
antibodies	O
in	O
blocking	O
solution	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
three	O
washes	O
with	O
PBS	O
,	O
cells	O
were	O
incubated	O
with	O
the	O
donkey	O
anti	O
-	O
rabbit	O
IgG	O
conjugated	O
with	O
FITC	O
or	O
anti	O
-	O
mouse	O
Cy3	O
(	O
1:200	O
,	O
Jackson	O
ImmunoResearch	O
Laboratories	O
)	O
.	O

Cells	O
were	O
then	O
washed	O
once	O
with	O
PBS	O
,	O
incubated	O
with	O
1:1000	O
DAPI	O
in	O
PBS	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
another	O
wash	O
with	O
PBS	O
.	O

Coverslips	O
were	O
mounted	O
onto	O
glass	O
slides	O
with	O
PVA	O
mounting	O
medium	O
containing	O
anti	O
-	O
fading	O
reagent	O
DABCO	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
mouse	O
anti	O
-	O
Oct3	O
/	O
4	O
(	O
1:500	O
,	O
Santa	O
Cruz	O
Biotechnology	O
Inc.	O
)	O
;	O
rabbit	O
anti	O
-	O
Ki67	O
(	O
1:200	O
,	O
Novocastra	O
Ltd.	O
)	O
;	O
rabbit	O
anti	O
-	O
TH	O
(	O
1:500	O
,	O
Chemicon	O
)	O
.	O

Immunostained	O
cell	O
cultures	O
were	O
visualized	O
using	O
a	O
Zeiss	O
fluorescent	O
microscope	O
attached	O
to	O
a	O
Nikon	O
digital	O
camera	O
.	O

Using	O
RT	O
-	O
PCR	O
,	O
all	O
RNA	O
samples	O
used	O
in	O
this	O
study	O
were	O
tested	O
negative	O
for	O
the	O
presence	O
of	O
gDNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
intron	O
-	O
spanning	O
primers	O
for	O
RT	O
-	O
PCR	O
were	O
selected	O
from	O
published	O
works	O
or	O
designed	O
using	O
Oligo	O
4.0	O
software	O
(	O
Molecular	O
Biology	O
Insight	O
)	O
or	O
Clone	O
Manager	O
Suite	O
7.1	O
(	O
Sci	O
Ed	O
Software	O
,	O
NC	O
,	O
USA	O
)	O
and	O
ordered	O
from	O
TAG	O
Copenhagen	O
A	O
/	O
S	O
,	O
Denmark	O
,	O
as	O
the	O
following	O
:	O
Sox2	O
,	O
SRY	O
-	O
box	O
2	O
:	O
5'-TAC	O
CTC	O
TTC	O
CTC	O
CC	O
CTC	O
CA-3	O
'	O
,	O
5'-ACT	O
CTC	O
CTC	O
TTT	O
TGC	O
ACC	O
CC-3	O
'	O
;	O
En1	O
,	O
Engrailed	O
1	O
:	O
5'-AAG	O
GGA	O
CGA	O
AAC	O
TGC	O
GAA	O
CTC	O
C-3	O
'	O
,	O
5'-GAC	O
ACG	O
AAA	O
GGA	O
AAC	O
ACA	O
CAC	O
TCT	O
CG-3	O
'	O
[	O
47	O
]	O
;	O
Nanog	O
:	O
5'-TGC	O
TTA	O
TTC	O
AGG	O
ACA	O
GCC	O
T-3	O
'	O
,	O
5'-TCT	O
GGT	O
CTT	O
CTG	O
TTT	O
CTT	O
GAC	O
T-3	O
'	O
[	O
48	O
]	O
;	O
Gapdh	O
,	O
glyceraldehydes-3-phosphate	O
dehydrogenase	O
:	O
5'-GGA	O
AGG	O
TGA	O
AGG	O
TCG	O
GAG	O
TCA	O
A-3	O
'	O
,	O
5'-GAT	O
CTC	O
GCT	O
CCT	O
GGA	O
AGA	O
TGG	O
T-3	O
'	O
;	O
Aldh1A1	O
,	O
aldehyde	O
dehydrogenase	O
1	O
family	O
,	O
member	O
A1	O
:	O
5'-GGG	O
CAG	O
CCA	O
TTT	O
CTT	O
CTC	O
AC-3	O
'	O
,	O
5'-CTT	O
CTT	O
AGC	O
CCG	O
CTC	O
AAC	O
AC-3	O
'	O
[	O
49	O
]	O
;	O
Sdha	O
,	O
succinate	O
dehydrogenase	O
:	O
5'-TGG	O
GAA	O
CAA	O
GAG	O
GGC	O
ATC	O
TG-3	O
'	O
,	O
5'-CCA	O
CCA	O
CTG	O
CAT	O
CAA	O
ATT	O
CAT	O
G-3	O
'	O
[	O
50	O
]	O
;	O
Tubb	O
,	O
Î²	O
-	O
tubulin	O
:	O
5'-CTC	O
ACA	O
AGT	O
ACG	O
TGC	O
CTC	O
GAG-3	O
'	O
,	O
5'-GCA	O
CGA	O
CGC	O
TGA	O
AGG	O
TGT	O
TCA-3	O
'	O
;	O
Nestin	O
:	O
5'-AGA	O
GGG	O
GAA	O
TTC	O
CTG	O
CT	O
GAG-3	O
'	O
,	O
5'-CTG	O
AGG	O
ACC	O
AGG	O
ACT	O
CTC	O
TA-3	O
'	O
[	O
47	O
]	O
;	O
Actb	O
,	O
Î²	O
-	O
actin	O
:	O
5'-CAT	O
CGA	O
GCA	O
CGG	O
CAT	O
CGT	O
CA-3	O
'	O
,	O
5'-TAG	O
CAC	O
AGC	O
CTG	O
GAT	O
AGC	O
AAC-3	O
'	O
[	O
51	O
]	O
;	O
Th	O
,	O
Tyrosine	O
hydroxylase	O
:	O
5'-CGA	O
GCT	O
GTG	O
AAG	O
GTG	O
TTT	O
G-3	O
'	O
,	O
5'-TTG	O
GTG	O
ACC	O
AGG	O
TGA	O
TGA	O
C-3	O
'	O
;	O
Msx1	O
,	O
homolog	O
of	O
Drosophila	O
muscle	O
segment	O
homolog	O
1	O
:	O
5'-CTC	O
AAG	O
CTG	O
CCA	O
GAA	O
GAT	O
GC-3	O
'	O
,	O
5'-TCC	O
AGC	O
TCT	O
GCC	O
TCT	O
TGT	O
AG-3	O
'	O
;	O
Pitx2	O
,	O
paired	O
-	O
like	O
homeodomain	O
transcription	O
factor	O
2	O
:	O
5'-ACC	O
TTA	O
CGG	O
AAG	O
CCC	O
GAG	O
TC-3	O
'	O
,	O
5'-TGG	O
ATA	O
GGG	O
AGG	O
CGG	O
ATG	O
TA-3	O
'	O
[	O
49	O
]	O
.	O

cDNA	O
was	O
synthesized	O
from	O
1	O
mg	O
of	O
total	O
RNA	O
using	O
SuperScript	O
II	O
(	O
Invitrogen	O
)	O
,	O
and	O
RT	O
-	O
PCR	O
amplifications	O
were	O
performed	O
using	O
the	O
MiniOpticon	O
system	O
(	O
Bio	O
-	O
Rad	O
)	O
with	O
REDTaq	O
Polymerase	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
essentially	O
as	O
described	O
by	O
the	O
manufacturer	O
.	O

Following	O
initial	O
denaturation	O
for	O
5	O
min	O
at	O
95	O
Â°	O
C	O
,	O
DNA	O
amplifications	O
were	O
performed	O
for	O
35	O
(	O
En1	O
,	O
Nanog	O
,	O
Aldh1a1	O
)	O
,	O
33	O
(	O
Sox2	O
,	O
Nestin	O
,	O
Th	O
,	O
Msx1	O
)	O
,	O
32	O
(	O
Tubb	O
,	O
Pitx2	O
)	O
,	O
27	O
(	O
Sdha	O
)	O
,	O
25	O
(	O
Actb	O
)	O
or	O
22	O
(	O
Gapdh	O
)	O
cycles	O
of	O
1	O
min	O
at	O
95	O
Â°	O
C	O
,	O
1	O
min	O
at	O
55	O
Â°	O
C	O
(	O
En1	O
,	O
Pitx2	O
)	O
,	O
57	O
Â°	O
C	O
(	O
Sox2	O
,	O
Nanog	O
,	O
Sdha	O
,	O
Nestin	O
)	O
,	O
58	O
Â°	O
C	O
(	O
Tubb	O
)	O
,	O
58.5	O
Â°	O
C	O
(	O
Aldh1a1	O
,	O
Th	O
)	O
or	O
59	O
Â°	O
C	O
(	O
Gapdh	O
,	O
Actb	O
,	O
Msx1	O
)	O
,	O
and	O
1	O
min	O
at	O
72	O
Â°	O
C	O
.	O

The	O
final	O
extension	O
was	O
5	O
min	O
at	O
72	O
Â°	O
C	O
.	O

Twenty	O
Î¼l	O
volumes	O
of	O
RT	O
-	O
PCR	O
products	O
were	O
analyzed	O
by	O
electrophoresis	O
at	O
1	O
%	O
agarose	O
gels	O
and	O
visualized	O
by	O
ethidium	O
bromide	O
staining	O
.	O

RNA	O
purification	O
and	O
fluorescent	O
dye	O
incorporationFor	O
RNA	O
purification	O
of	O
undifferentiated	O
hESCs	O
,	O
the	O
latter	O
were	O
mechanically	O
separated	O
from	O
hFCs	O
,	O
collected	O
in	O
a	O
500	O
Î¼l	O
volume	O
of	O
VitroHES	O
media	O
,	O
rinsed	O
in	O
PBS	O
buffer	O
and	O
spun	O
down	O
at	O
300	O
rcf	O
for	O
5	O
min	O
.	O

hESC	O
-	O
derived	O
cells	O
grown	O
atop	O
PA6	B
cells	O
were	O
harvested	O
using	O
a	O
papain	O
dissociation	O
kit	O
(	O
Worthington	O
Biochemical	O
Corporation	O
)	O
,	O
rinsed	O
in	O
PBS	O
buffer	O
and	O
spun	O
down	O
as	O
described	O
above	O
.	O

The	O
resulting	O
cell	O
pellets	O
were	O
resuspended	O
in	O
RLT	O
buffer	O
(	O
Qiagen	O
,	O
USA	O
)	O
,	O
passed	O
through	O
the	O
shredder	O
column	O
(	O
Qiagen	O
)	O
and	O
stored	O
at	O
-80	O
Â°	O
C	O
until	O
the	O
RNA	O
sample	O
was	O
purified	O
following	O
the	O
RNeasy	O
Micro	O
Kit	O
(	O
Qiagen	O
)	O
protocol	O
(	O
without	O
carrier	O
RNA	O
)	O
;	O
with	O
DNase	O
I	O
(	O
Quiagen	O
)	O
treatment	O
incorporated	O
to	O
the	O
latter	O
.	O

RNA	O
integrity	O
was	O
tested	O
using	O
both	O
ND-1000	O
specrophotometer	O
(	O
NanoDrop	O
,	O
USA	O
)	O
and	O
RNA	O
Nano	O
LabChip	O
/	O
2100	O
Bioanalyzer	O
system	O
(	O
Agilent	O
Technologies	O
,	O
USA	O
)	O
.Fluorescent	O
label	O
(	O
24	O
nmol	O
of	O
the	O
Cyanine	O
3-CTP	O
(	O
Cy3	O
)	O
;	O
PerkinElmer	O
,	O
USA	O
)	O
was	O
incorporated	O
to	O
350â500	O
ng	O
of	O
total	O
RNA	O
amplified	O
using	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
Kit	O
(	O
Agilent	O
Technologies	O
)	O
,	O
generally	O
following	O
the	O
kit	O
manufacturer	O
's	O
protocol	O
.	O

Similarly	O
,	O
24	O
nmols	O
of	O
the	O
Cyanine	O
5-CTP	O
(	O
Cy5	O
;	O
PerkinElmer	O
)	O
fluorescent	O
label	O
were	O
incorporated	O
to	O
400	O
ng	O
sample	O
of	O
Human	O
Universal	O
Reference	O
RNA	O
(	O
Stratagene	O
,	O
USA	O
)	O
;	O
in	O
addition	O
,	O
dye	O
-	O
swap	O
replicate	O
amplification	O
were	O
performed	O
.	O

Amplified	O
fluorescent	O
cRNA	O
samples	O
were	O
purified	O
using	O
RNeasy	O
mini	O
-	O
columns	O
(	O
Quiagen	O
)	O
,	O
and	O
fluorescence	O
of	O
the	O
eluted	O
products	O
was	O
measured	O
using	O
ND-1000	O
specrophotometer	O
(	O
NanoDrop	O
)	O
.	O

Microarray	O
technologyLong	O
oligonucleotide	O
probes	O
(	O
69â71	O
nucleotides	O
)	O
matching	O
gene	O
targets	O
of	O
interest	O
were	O
selected	O
from	O
Operon	O
V2	O
and	O
V3	O
human	O
AROS	O
sets	O
(	O
Operon	O
Biotechnologies	O
Inc.	O
,	O
USA	O
)	O
.	O

Arrays	O
were	O
produced	O
by	O
the	O
SweGene	O
DNA	O
Microarray	O
Resource	O
Centre	O
,	O
Department	O
of	O
Oncology	O
at	O
Lund	O
University	O
(	O
Sweden	O
)	O
using	O
a	O
MicroGrid	O
II	O
600R	O
arrayer	O
fitted	O
with	O
MicroSpot	O
10	O
K	O
pins	O
(	O
Harvard	O
BioRobotics	O
,	O
USA	O
)	O
.	O

Printing	O
was	O
performed	O
in	O
a	O
temperature-	O
(	O
18â20	O
Â°	O
C	O
)	O
and	O
humidity-	O
(	O
44â49	O
%	O
RH	O
)	O
controlled	O
area	O
on	O
Corning	O
UltraGAPS	O
aminosilane	O
slides	O
(	O
Corning	O
Inc.	O
,	O
USA	O
)	O
with	O
140	O
Î¼m	O
spot	O
-	O
to	O
-	O
spot	O
centerdistance	O
and	O
90â110	O
Î¼m	O
average	O
spot	O
size	O
.	O

Following	O
printing	O
,	O
arrays	O
were	O
dried	O
for	O
48	O
hours	O
andstored	O
in	O
a	O
dessicator	O
until	O
used	O
.	O

Microarray	O
slides	O
were	O
UV	O
-	O
cross	O
-	O
linked	O
(	O
800	O
mJ	O
/	O
cm2	O
)	O
,	O
pre	O
-	O
hybridizedwith	O
fluorescently	O
labeled	O
samples	O
using	O
the	O
Pronto	O
!	O

Universal	O
Microarray	O
Hybridization	O
Kit	O
(	O
Corning	O
)	O
and	O
subsequently	O
hybridized	O
with	O
test	O
(	O
Cy3-labeled	O
)	O
/	O
reference	O
(	O
Cy5-labeled	O
)	O
RNA	O
samples	O
(	O
or	O
in	O
reverse	O
dye	O
-	O
labeling	O
order	O
)	O
at	O
42	O
Â°	O
C	O
for	O
17	O
h	O
using	O
a	O
MAUI	O
hybridization	O
station	O
(	O
BioMicro	O
Systems	O
Inc.	O
,	O
USA	O
)	O
and	O
the	O
Pronto	O
!	O

Universal	O
Microarray	O
Hybridization	O
Kit	O
,	O
generally	O
following	O
manufacturer	O
's	O
instructions	O
,	O
with	O
several	O
minor	O
adaptations	O
[	O
31	O
]	O
.	O

Data	O
acquisition	O
and	O
statistical	O
analysisImmediately	O
following	O
the	O
washing	O
steps	O
,	O
the	O
fluorescence	O
intensities	O
were	O
measured	O
using	O
a	O
confocal	O
laser	O
scanner	O
(	O
G2505B	O
,	O
Agilent	O
Technologies	O
)	O
.	O

After	O
image	O
formatting	O
by	O
Tiff	O
Image	O
Channel	O
Splitter	O
Utility	O
(	O
Agilent	O
Technologies	O
)	O
and	O
grid	O
annotation	O
,	O
a	O
complete	O
set	O
of	O
spots	O
was	O
visually	O
inspected	O
for	O
each	O
slide	O
.	O

Using	O
GenePix	O
Pro	O
(	O
Molecular	O
Devices	O
Corp.	O
USA	O
)	O
flags	O
for	O
artifactual	O
spots	O
were	O
annotated	O
for	O
each	O
spot	O
.	O

Median	O
pixel	O
intensity	O
minus	O
the	O
median	O
local	O
background	O
for	O
both	O
dyes	O
was	O
used	O
to	O
obtain	O
a	O
test	O
over	O
reference	O
intensity	O
ratio	O
.	O

Data	O
normalization	O
was	O
performed	O
per	O
array	O
subgrid	O
using	O
LOWESS	O
curve	O
fitting	O
with	O
a	O
smoothing	O
factor	O
of	O
0.33	O
[	O
52,53	O
]	O
.	O

All	O
normalizations	O
,	O
filtering	O
,	O
merging	O
of	O
technical	O
replicates	O
and	O
analyses	O
were	O
performed	O
in	O
the	O
BioArray	O
Software	O
Environment	O
database	O
[	O
32	O
]	O
.	O

To	O
visualize	O
sample	O
-	O
dependent	O
variation	O
of	O
spot	O
intensities	O
,	O
data	O
was	O
uploaded	O
to	O
the	O
TIGR	O
MultiExperiment	O
Viewer	O
(	O
MEV	O
;	O
[	O
34	O
]	O
)	O
.	O

